Direct medical cost related to the management of pemphigus: A pilot Tunisian study

##plugins.themes.academic_pro.article.sidebar##

Published Feb 18, 2024
https://doi.org/10.62438/tunismed.v102i2.4651
Download
pdf
Vol. 102 No. 2 (2024): Tunis med feb 2024

##plugins.themes.academic_pro.article.main##

Faten Hayder
Department of dermatology, Hedi Chaker University Hospital, Sfax, Tunisia
Emna Bahloul
Department of dermatology, Hedi Chaker University Hospital, Sfax, Tunisia
Sourour Yaich
Department of community Health and Epidemiology, Hedi Chaker University Hospital, Sfax, Tunisia
Sana Turki
Department of pharmacy, Hedi Chaker University Hospital, Sfax, Tunisia
Khadija Sellami
Department of dermatology, Hedi Chaker University Hospital, Sfax, Tunisia
Noureddine Litaiem
Department of dermatology, University of Tunis El Manar, Tunis, Tunisia
Hatem Masmoudi
Department of immunology, Habib Bourguiba Hospital, Sfax, Tunisia
Manel Turki
Department of pharmacy, Hedi Chaker University Hospital, Sfax, Tunisia
Hamida Turki
Department of dermatology, Hedi Chaker University Hospital, Sfax, Tunisia

Abstract

Background: Pemphigus is a therapeutically challenging disease with high morbidity and economic burden. First-line prescription of rituximab remains limited in Tunisia due to its high cost. Systemic steroids remain the standard of care but are associated with a major risk of morbidities and higher treatment costs.


Aim: To assess the direct medical costs of pemphigus in Tunisia.


Methods: Retrospective estimation of direct medical costs during the 18 months following the diagnosis using the “bottom-up approach” in the Dermatology Department of Hedi Chaker Hospital, Sfax, Tunisia.


Results: Total medical costs were estimated at 38745.7 €, with an average cost of 1 210 € per patient and per year: paraclinical investigations (46%), medical treatment (30%), hospitalization (21%) and outpatient visits (3%). The average cost was the highest in the age group of 15-24 years (1553 €). Treatment costs related to corticosteroid-induced morbidity were estimated at 1208 €.


Conclusions: The management of pemphigus in Tunisia needs to be adapted to take into account the health economic analysis in order to reduce overall disease costs and the burden of steroid-induced morbidities.

Keywords:

Pemphigus, Tunisia, Cost, Corticosteroids

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Bastuji-Garin S, Souissi R, Blum L, Turki H, Nouira R, Jomaa B, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol 1995;104(2):302-5. DOI: 10.1111/1523-1747.ep12612836.
  2. Sellami K, Bouchaala M, Bahloul E, Masmoudi A, Boudaya S, Mseddi M, et al. Pemphigus superficiel : notre expérience dans l’ère pré-rituximab. Ann Dermatol Venereol 2019;146(12):A164‑5.
  3. Iddir K, Fenina N, Lassoued M, Zmerli R, Zeghal S, Haltiti L, et al. Formulaire thérapeutique tunisien. 3ème ed. Tunis : Direction de la Pharmacie et du Médicament; 2012.
  4. République Tunisienne. Arrêté des ministres des finances et de la santé publique du 19 décembre 1996, fixant les tarifs de la prise en charge des malades payants dans les structures sanitaires publiques relevant du ministère de la santé publique. Journal Officiel du 11 juillet 2008.
  5. République Tunisienne. Arrêté du ministre de la sante publique du 01 Juin 2006, fixant la nomenclature générale des actes professionnels des médecins, biologistes, médecins dentistes, psychologues cliniciens, sages-femmes et auxiliaires médicaux. Journal Officiel du 9 juin 2006.
  6. Instance Nationale de l’Evaluation et de l’Accréditation en Santé (INEAS). Evaluation des technologies de santé. Choix méthodologiques pour les études pharmaco-économiques à l’INEAS. Tunis : INEAS ; 2021/ 44 pages.
  7. Hebert V, Vermeulin T, Prost-Squarcioni C, Picard-Dahan C, Duvert-Lehembre S, Bruno L, et al. Comparaison des coûts de santé du traitement de première ligne par rituximab par rapport à la corticothérapie standard chez les patients pemphigus nouvellement diagnostiqués. Ann Dermatol Venereol 2018;145(12):S51‑2.
  8. Heelan K, Hassan S, Bannon G, Knowles S, Walsh S, Shear NH, et al. Cost and resource use of pemphigus and pemphigoid disorders pre- and post-rituximab. J Cutan Med Surg 2015;19(3):274‑82.
  9. Kanchan R, Kamoji SG, Ningappa Patil M. To compare the cost of rituximab and DCP therapy in pemphigus in a government tertiary hospital. J Clin Exp Dermatol Res 2017;8(2):1-4.
  10. Brodszky V, Tamási B, Hajdu K, Péntek M, Szegedi A, Sárdy M, et al. Disease burden of patients with pemphigus from a societal perspective. Expert Rev Pharmacoecon Outcomes Res 2021;21(1):77‑86.
  11. Best JH, Michalska M, Abbass I. Burden of illness of treating patients with pemphigus vulgaris. Hypertension 2018;147:23.3.
  12. Hsairi M, Braham MB, Gamara D, Fourati R, Abid F, Tritar F, et al. Coût de la tuberculose en Tunisie. Tunis Med 2016;94(10):604-11.
  13. Bahloul E, Masmoudi A, Jerbi A, Abida O, Hachicha H, Mesrati H, et al. Le pemphigus foliacé érythrodermique: une série hospitalière du Sud tunisien. Ann Dermatol Venereol 2019;146(12):A160.
  14. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009;103(7):975‑94.
  15. Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. StatPearls [Internet]. 2022 May [Cited 2023 Jan 20]. Available from:https: //www.ncbi.nlm.nih.gov/books/NBK531462/.
  16. Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 2017;39(11):2216‑29.
  17. Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 2011;33(10):1413‑32.